| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-077 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-34 |
| filingDate |
2021-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7326db3c65106ae130e4e8d911eb134d |
| publicationDate |
2022-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022026851-A1 |
| titleOfInvention |
Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna |
| abstract |
The protein targeted medicine, Dovitinib, has been repurposed to target a non-coding RNA by using selection and computational drug design via Inforna. Selectivity was achieved for pre-miR-21 by endowing the medicine with the ability to recruit RNA quality control enzymes to cleave the target. |
| priorityDate |
2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |